Pacific Biosciences of California (PACB) reported $39.97 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 28.2%. EPS of -$0.17 for the same period compares to -$0.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $41.9 million, representing a surprise of -4.60%. The company delivered an EPS surprise of +15.00%, with the consensus EPS estimate being -$0.20.While investors scrutinize revenue and earnings changes year-over-year and h ...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.24 per share when it actually produced a loss of $0.20, delivering a surprise of 16.67%.Over the ...

Core Viewpoint - PacBio has launched the Vega™ system, a benchtop long-read sequencing platform that combines affordability and precision, aimed at expanding access to advanced sequencing technology for researchers [1][2]. Product Features - The Vega system is priced at $169,000 and offers high data accuracy with HiFi technology, fast turnaround times, and compatibility with existing HiFi ecosystems for library preparation and data analysis [1][2]. - It can process 600 full-length RNA samples per year, 9,600 samples using the PureTarget repeat expansion panel, or 200 human genomes per run [2]. - The system features an integrated workflow with only two consumables and is supported by SMRT Link Cloud software for easier management [4]. Market Impact - The Vega system is expected to enhance the capabilities of researchers in various applications, including targeted sequencing, RNA sequencing, and small genome sequencing [2][5]. - Initial testing has shown that the Vega instrument is fast and simple, making it suitable for clinical applications, particularly in China [3]. - The launch is seen as a significant step in making HiFi long-read sequencing technology more accessible to a broader range of researchers [4][6]. Company Strategy - PacBio's strategy includes building a portfolio of innovative products that meet diverse research demands, following the launch of the Revio system in early 2023 [2]. - The company aims to empower researchers to explore new scientific frontiers by raising the bar for data quality and accessibility [2].

MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide. The ...

Pacific Biosciences of California (PACB) closed the latest trading day at $2.06, indicating a -1.9% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.47% for the day. Elsewhere, the Dow saw an upswing of 0.79%, while the tech-heavy Nasdaq appreciated by 0.28%. Shares of the maker of genetic analysis technology witnessed a gain of 12.3% over the previous month, beating the performance of the Medical sector with its loss of 4.27% and the S&P 500's gain o ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings and product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. In the year-to-date period, this Zacks Rank #3 (Hold) company's shares have lost 79.1% against 6.6% growth of the industry. The S&P 500 composite has also gained 21.9% in the ...

Pacific Biosciences, Inc. (PACB) , popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Leveraging PacBio's Onso short-read sequencing platform, the collaboration aims to enable researchers to profile the genomic landscape of prevalent cancers, including gastrointestinal stromal tumors. PacBio's partner, Diethelm Keller Siber Hegner (DKSH), a Swiss company specializing in market expansion services, ...

Core Viewpoint - PacBio will hold its quarterly conference call to discuss its third quarter 2024 financial results on November 7, 2024, at 4:30 pm Eastern Time [1] Company Overview - Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a leading life science technology company that designs, develops, and manufactures advanced sequencing solutions [2] - The company focuses on two core technologies: HiFi long-read sequencing and SBB® short-read sequencing, emphasizing accuracy, quality, and completeness [2] - PacBio's products are utilized in various research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [2]

Company Overview - Pacific Biosciences of California (PACB) closed at $1.81, reflecting a +0.56% change from the previous trading day's close, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, PACB shares have increased by 6.51%, surpassing the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [2] Financial Performance Expectations - The upcoming financial results are anticipated to show an EPS of -$0.20, which represents a 25.93% increase compared to the same quarter last year. Revenue is expected to be $41.9 million, indicating a 24.77% decrease year-over-year [3] - For the entire year, the Zacks Consensus Estimates forecast an EPS of -$0.95 and revenue of $168.07 million, reflecting changes of +14.41% and -16.18% respectively compared to the previous year [4] Analyst Estimates and Market Sentiment - Recent changes to analyst estimates for PACB suggest a shifting business landscape, with positive revisions indicating optimism about the company's outlook [5] - The Zacks Rank system, which correlates estimate revisions with share price momentum, currently ranks PACB as 3 (Hold), with a 9.17% decrease in the consensus EPS estimate over the last 30 days [6][7] Industry Context - The Medical - Instruments industry, which includes PACB, holds a Zacks Industry Rank of 63, placing it in the top 25% of over 250 industries. This ranking indicates that top-rated industries tend to outperform lower-rated ones by a factor of 2 to 1 [8]

Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women's and Children's Hospital in Singapore. The consortium will use PACB's HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the AsiaPacific region and leverages DNAstack's federated data platform to ensure secure, global co ...